Skip to main content
Epigenetics & Chromatin logoLink to Epigenetics & Chromatin
. 2020 Nov 23;13:51. doi: 10.1186/s13072-020-00372-6

Comparison of methylation capture sequencing and Infinium MethylationEPIC array in peripheral blood mononuclear cells

Chang Shu 1,2, Xinyu Zhang 1,2, Bradley E Aouizerat 3,4, Ke Xu 1,2,
PMCID: PMC7684759  PMID: 33228774

Abstract

Background

Epigenome-wide association studies (EWAS) have been widely applied to identify methylation CpG sites associated with human disease. To date, the Infinium MethylationEPIC array (EPIC) is commonly used for high-throughput DNA methylation profiling. However, the EPIC array covers only 30% of the human methylome. Methylation Capture bisulfite sequencing (MC-seq) captures target regions of methylome and has advantages of extensive coverage in the methylome at an affordable price.

Methods

Epigenome-wide DNA methylation in four peripheral blood mononuclear cell samples was profiled by using SureSelectXT Methyl-Seq for MC-seq and EPIC platforms separately. CpG site-based reproducibility of MC-seq was assessed with DNA sample inputs ranging in quantity of high (> 1000 ng), medium (300–1000 ng), and low (150 ng–300 ng). To compare the performance of MC-seq and the EPIC arrays, we conducted a Pearson correlation and methylation value difference at each CpG site that was detected by both MC-seq and EPIC. We compared the percentage and counts in each CpG island and gene annotation between MC-seq and the EPIC array.

Results

After quality control, an average of 3,708,550 CpG sites per sample were detected by MC-seq with DNA quantity > 1000 ng. Reproducibility of DNA methylation in MC-seq-detected CpG sites was high among samples with high, medium, and low DNA inputs (r > 0.96). The EPIC array captured an average of 846,464 CpG sites per sample. Compared with the EPIC array, MC-seq detected more CpGs in coding regions and CpG islands. Among the 472,540 CpG sites captured by both platforms, methylation of a majority of CpG sites was highly correlated in the same sample (r: 0.98–0.99). However, methylation for a small proportion of CpGs (N = 235) differed significantly between the two platforms, with differences in beta values of greater than 0.5.

Conclusions

Our results show that MC-seq is an efficient and reliable platform for methylome profiling with a broader coverage of the methylome than the array-based platform. Although methylation measurements in majority of CpGs are highly correlated, a number of CpG sites show large discrepancy between the two platforms, which warrants further investigation and needs cautious interpretation.

Keywords: Methylation capture sequencing, EPIC, DNA methylation, Peripheral blood mononuclear cells

Introduction

The rapid increase in the number of epigenome-wide association studies (EWAS) have successfully identified differentially methylated CpG sites that are associated with environmental exposures and diseases [16]. Such DNA methylation marks have been used as biomarkers for diagnosing, subtyping, and monitoring disease progression [711]. The most popular and affordable methods to profile epigenome-wide DNA methylation are array-based platforms, primarily the Illumina Human Methylation 450 K (450 K) and Infinium MethylationEPIC (EPIC) BeadChips (Illumina Inc, San Diego, CA). These arrays utilize Illumina’s beadchip technology that does not require polymerase chain reaction (PCR), but is subject to dye intensity biases between the two platforms [12]. These arrays have limited coverage of the methylome and can only detect up to 870,000 CpGs across the epigenome, leaving a large proportion of CpG sites unmeasured. Moreover, the EPIC array offers improved but still suboptimal coverage of regulatory elements [13]. Whole-genome bisulfite sequencing (WGBS) is able to capture more than 28 million CpGs, but the feasibility remains low for the population-based EWAS due to high cost and large genomic DNA input requirements to compensate for degradation during DNA bisulfite treatment. Alternatively, Methylation Capture Sequencing (MC-seq) is able to detect DNA methylation at single-nucleotide resolution utilizing a targeted next-generation sequencing approach [14]. It permits profiling of significantly more CpG sites than the EPIC array, requires less genomic DNA input than WGBS, and less expensive than WGBS, but can be susceptible to bias due to the presence of PCR duplicates. Feature-to-cost comparisons among different platforms can help understand the utilities of each platform and provide guidance for investigators in choosing a methylation profiling platform.

A few studies have compared the CpG coverage, reproducibility, and performance of array-based and MC-seq platforms [1517]. Teh et al. compared MC-seq and the 450 K array in seven DNA samples extracted from saliva [15]. A recent study compared the EPIC array and TruSeq targeted bisulfite sequencing in four cord blood DNA samples [17]. However, no comparisons of MC-seq and array-based methylome profiling of peripheral blood mononuclear cells (PBMCs) has been reported. Here, we profiled the DNA methylome in PBMCs using the Agilent SureSelect Methyl-Seq platform and compared the results to the EPIC array in DNA samples extracted from PBMCs.

Methods

Methylation capture sequencing (MC-seq)

DNA samples description

DNA was extracted from de-identified PBMCs collected from four individuals. Genomic DNA quality was determined by estimating the A260/A280 and A260/A230 ratios by spectrophotometry and concentration by fluorometry. DNA integrity and fragment size were confirmed using a microfluidic chip run on an Agilent Bioanalyzer. To assess the reproducibility of MC-seq by DNA quantity, DNA samples from each participant were profiled in triplicate times with high (> 1000 ng), medium (300–1000 ng), and low (150–300 ng) DNA input. In total, 12 DNA samples were measured by MC-seq. Bisulfate conversion was conducted for each DNA sample as described below.

Methyl-seq target enrichment library prep

Indexed paired-end whole-genome sequencing libraries were prepared using the SureSelect XT Methyl-Seq kit (Agilent, part#G9651B). Genomic DNA was sheared to a fragment length of 150–200 bp using focused acoustic energy delivered by the Covaris E220 system (Covaris, part#500003). Fragmented sample size distribution was determined using the Caliper LabChip GX system (PerkinElmer, Part#122000). Fragmented DNA ends were repaired with T4 DNA Polymerase and Polynucleotide Kinase and “A” base was added using Klenow fragment in a single reaction followed by AMPure XP bead-based purification (Beckman Coulter, part#A63882). The methylated adapters were ligated using T4 DNA ligase followed by AMPure XP bead purification. Quality and quantity of adapter-ligated DNA were assessed using the Caliper LabChip GX system. Samples yielding > 350 ng were enriched for targeted methylation sites by using the custom SureSelect Methyl-Seq Capture Library. Hybridization was performed at 65 °C for 16 h using a C1000 Thermal Cycler (BIO-RAD, part# 1851197). Once the enrichment was completed, the samples were mixed with streptavidin-coated beads (Thermo Fisher Scientific, part#65602) and washed with a series of buffers to remove non-specific bound DNA fragments. DNA fragments were eluted from beads with 0.1 M NaOH. Unmethylated C residues of enriched DNA were modified by bisulfite conversion using the EZ DNA Methylation-Gold Kit (Zymo Research, part#D5005). The SureSelect enriched, bisulfite-converted libraries were PCR amplified using custom-made indexed primers (IDT, Coralville, Iowa). Dual-indexed libraries were quantified by quantitative polymerase chain reaction (qPCR) using the Library Quantification Kit (KAPA Biosystems, Part#KK4854) and inserts size distribution was assessed using the Caliper LabChip GX system. Samples with a yield of ≥ 2 ng/μl were proceeded to sequencing.

Flow cell preparation and sequencing

Sample concentrations were normalized to 10 nM and loaded onto an Illumina NovaSeq flow cell at a concentration that yields 40 million passing filter clusters per sample. Samples were sequenced using 100 bp paired-end sequencing on an Illumina HiSeq NovaSeq according to Illumina standard protocol. The 10 bp dual index was read during additional sequencing reads that automatically follows the completion of the first read. Data generated during sequencing runs were simultaneously transferred to the Yale Center for Genome Analysis high-performance computing cluster. A positive control (prepared bacteriophage Phi X library) provided by Illumina was spiked into every lane at a concentration of 0.3% to monitor sequencing quality in real time.

Preprocessing and quality control

Signal intensities were converted to individual base calls during a run using the system’s Real Time Analysis (RTA) software. Sample de-multiplexing and alignment to the human genome was performed using Illumina’s CASAVA 1.8.2 software suite. The sample error rate was required to be less than 1% and the distribution of reads per sample in a lane was required to be within reasonable tolerance.

Quality control (QC) on MC-seq was conducted following standard procedure as previously described [18]. Quality of sequence data was examined by using FastQC (ver. 0.11.8). Adapter sequences and fragments at 5′ and 3′ (phred score < 20) with poor quality were removed by Trim_galore (ver. 0.6.3_dev). We used Bismark pipelines (ver. v0.22.1_dev) to align the reads to the bisulfite human genome (hg19) with default parameters [19]. Quality-trimmed paired-end reads were transformed into a bisulfite converted forward strand version (C → T conversion) or into a bisulfite-treated reverse strand (G → A conversion of the forward strand). Duplicated reads were removed from the Bismark mapping output by deduplicate_bismark and CpG, CHG, and CHH (where H = A, T, or C) were extracted by bismark_methylation_extractor.

All CpG sites were grouped by sequencing coverage, also known as read depth. The groups with coverage of 1× to 100× were used to test the relationship between coverage and number of CpG sites. Only the CpG sites with coverage > 10× depth were used for final comparisons to ensure MC-seq data quality. Genes were annotated using Homer annotatePeaks.pl, including intergenic, 5′UTR, promoter, exon, intron, 3′UTR, transcription start site (TTS), and non-coding categories. CpG island, shore, shelf, and open sea annotation were defined by locally developed bash and R scripts based on genomic coordinates (hg19) of CpG islands from the UCSC genome browser. CpG shores was defined as up to 2 kb from CpG islands and CpG shelf was defined as up to 2 kb from a CpG shore.

Assessment of reproducibility

We assessed CpG- and participant-based reproducibility for MC-seq among 12 samples with DNA quantity of high, medium, and low input in two ways. First, CpG-based reproducibility was assessed by calculating Pearson correlations using the CpG sites in common of the samples from the same participant with different input DNA quantities. Scatterplots were rendered showing 10,000 randomly selected common CpG sites comparing samples with high and medium, high and low, and medium and low DNA inputs. Second, participant-based reproducibility was assessed by comparing methylation profiles among pairs of participants using the samples with high DNA inputs, by calculating Pearson correlations of common CpG sites.

EPIC array data preprocessing

The Infinium MethylationEPIC array (Illumina, San Diego, CA, USA) was used to measure PBMC DNA methylation profiles from the same four participants. These four samples with DNA input of 1000 ng were preprocessed using standard procedures as previously described [20]. Briefly, the predicted sex based on methylome was consistent with self-reported sex for all samples. All samples had a call rate greater than 0.15. A total of 19,090 CpG sites on X chromosomes and 537 CpG sites on Y chromosomes were filtered. A total of 846,464 CpG sites passed quality control.

Comparison of methylation at each CpG site between MC-seq and EPIC array

The overall distribution of gene annotation in relation to CpG island and genetic region between MC-seq and EPIC array data from the four participants was compared. Common CpG sites between MC-seq and EPIC array assays were defined according to genomic coordinates. Pearson correlation and the absolute beta-difference value (Δβ) were calculated among common CpG sites between MC-seq methylation percentage values and EPIC methylation beta values by using R (ver. 3.5.1). If median Δβ of the common CpG site between two platforms was > 0.1, it was defined as a discordant CpG pair; otherwise, the CpG site was defined as a concordant CpG pair. The density plot of Δβ and a Manhattan plot showing the distribution of Δβ across epigenome were illustrated. Scatterplots were rendered showing the correlation of β values from 10,000 randomly selected CpG sites measured by both MC-seq and EPIC array.

Results

MC-seq overview and reproducibility

In MC-seq, all sequences were efficiently mapped to the reference genome with greater than 89% mapping efficiency. Interestingly, the number of non-CpG sites was significantly greater than the number of CpG sites. Among all detected methylation sites by MC-seq, 11% were CpG sites, 65% were CHH sites, and 24% were CHG sites (Fig. 1a).

Fig. 1.

Fig. 1

Methylation Capture Sequencing (MC-seq). a Distribution of methylation sequence context (CpG, CHH, CHG); b Coverage depth versus a number of detected CpG sites; c Detected CpG sites in low, medium, and high DNA inputs for four participants using MC-seq with minimum coverage ≥ 10×; d Scatterplots comparing 10,000 randomly selected common CpG sites among samples with high, medium, and low DNA input quantities and their Pearson correlations

Figure 1b shows the relationship of the number of detected CpG sites and depth of sequence coverage by MC-seq in one sample. The depth of read at which the majority of sites were sequenced was estimated to be approximately 10× coverage, observed as the inflection point of the distribution of Fig. 1b. An increase of depth only slightly increased the capture of CpG sites and the inflection point is on 10× coverage, consistent with previous literature [15, 17]. Thus, the number of CpG sites with coverage ≥ 10× from MC-seq was used in subsequent analyses.

After quality control filtering, MC-seq captured an average of 2,878,207 methylation CpG sites with coverage ≥ 10× among the 12 DNA samples, with an average of 3,708,550 CpG sites among samples with high DNA input (> 1000 ng), an average of 3,046,172 CpG sites among samples with medium DNA input (300–1000 ng), and an average of 1,879,898 CpG sites among samples with low DNA input (150–300 ng) (Fig. 1c and Table 1). Despite the fact that the detected number of CpG sites varied depending on DNA input quantity, CpG-based correlation among the common CpG sites between samples with high and medium, high and low DNA input quantities exceeded r > 0.95. Correlations of common CpG sites between medium and low DNA inputs were also high with r in 0.92–0.94 (Table 2). Figure 1d shows the scatterplot of 10,000 randomly selected common CpGs between samples with high and medium, high and low, and medium and low DNA input quantities. Pair-wise participant-based correlations were high as r > 0.98 among common CpG sites (Table 3). Overall, MC-seq exhibited good reproducibility. The methylation profile generating in high DNA input from each participant was used for subsequent analyses.

Table 1.

Detected CpG number by DNA amount in MC-seq with coverage ≥ 10×

DNA amount Participant ID CpG number Average CpG number
Low S1 1,774,940 1,879,898
S2 1,831,086
S3 2,154,732
S4 1,758,834
Medium S1 2,768,456 3,046,172
S2 3,338,200
S3 3,119,259
S4 2,958,772
High S1 3,406,879 3,708,550
S2 3,642,776
S3 3,722,552
S4 4,061,994
Total average 2,878,207

Table 2.

Comparison of MC-seq between samples with high, medium, and low DNA input amount

Participant ID DNA amount
High Medium Common CpG Pearson correlation
S1 3,406,879 2,768,456 2,747,844 0.984
S2 3,642,776 3,338,200 3,283,296 0.984
S3 3,722,552 3,119,259 3,101,938 0.977
S4 4,061,994 2,958,772 2,957,239 0.979
DNA amount
High Low Common CpG Pearson correlation
S1 3,406,879 1,774,940 1,771,936 0.960
S2 3,642,776 1,831,086 1,829,919 0.966
S3 3,722,552 2,154,732 2,153,175 0.974
S4 4,061,994 1,758,834 1,758,622 0.963
DNA amount
Medium Low Common CpG Pearson correlation
S1 2,768,456 1,774,940 1,745,241 0.942
S2 3,338,200 1,831,086 1,827,536 0.943
S3 3,119,259 2,154,732 2,135,980 0.939
S4 2,958,772 1,758,834 1,744,416 0.928

Table 3.

Overlap of detected CpG across samples with high DNA input amount by MC-seq

Participant ID 1 Participant ID 2 Common CpG Pearson R
S1 S2 3,336,037 0.980
S1 S3 3,350,314 0.976
S1 S4 3,394,970 0.982
S2 S3 3,519,772 0.978
S2 S4 3,613,753 0.982
S3 S4 3,676,406 0.978

Distribution of methylome regions by MC-seq and EPIC

We compared genome-wide DNA methylation captured by MC-seq and by EPIC array in the four high DNA input samples. An average of 3,708,550 CpG sites were detected by MC-seq and 846,464 CpG sites by EPIC array. Overall, MC-seq detected 11.5 times more CpG sites in exons and 10.2 times more CpG sites in 5′ UTR region compared to the EPIC array, and 4.8 to 8.9 times more CpG site in other categories of genomic regions by MC-seq compared to EPIC array. However, the proportion of CpGs out of all CpGs successfully measured that map to gene regions in MC-seq as compared to the EPIC array did not significantly differ between these two platforms. For example, the proportion of CpG sites in transcription termination site (TTS) regions was similar between two platforms. MC-seq showed slightly greater proportions of CpG sites in 5′UTR and exon regions, while the EPIC array detected a greater proportion of CpG sites in promoter regions (Fig. 2a). In terms of CpG sites in relation to CpG islands including open seas, shelves, and shores, MC-seq detected 10.9 times more CpG sites located on CpG islands and 5.4–6.2 times more on other regions compared with the EPIC array. The proportion of CpG islands detected by MC-seq was greater than by the EPIC array (42% versus 29%), while the EPIC array detected a modestly higher percentage of CpG sites located in open seas than the MC-seq (39% versus 31%) (Fig. 2b).

Fig. 2.

Fig. 2

Comparison of CpG proportion in epigenomic regions between MC-seq and EPIC. a Distribution of genomic regions (intergenic, promoter, 5′UTR, exon, intron, non-coding, 3′UTR, transcription termination site (TTS), and non-coding). b Distribution of CpG position relative to CpG islands (CpG island, shore, shelf, and open sea)

Comparison of Common CpG sites Measured by MC-seq and EPIC

A total of 472,540 CpG sites were measured by both platforms. Overall, the correlations of these shared CpG sites was high, ranging from r = 0.983 to 0.985 across the four samples (Fig. 3a). Figure 3b presents the distribution of the absolute difference of methylation β values between MC-seq and EPIC. A small proportion of CpG sites (1.4%) were discordant (i.e., Δβ > 0.1), while 98.6% of CpG sites were concordant (i.e., Δβ < 0.1). Figure 3a presents the concordant (blue) and discordant CpG sites (green) between MC-seq and EPIC for participant S1 (Fig. 3a). The 60,753 discordant CpG sites appeared to be randomly distributed across the epigenome (Additional file 1: Figure S1). Among the discordant CpG sites, we identified 239 CpG sites with highly discrepant methylation (i.e., Δβ > 0.5) (Table 4). Addition file 2: Table S1 presents top 100 discordant CpG sites with medium discrepant methylation (Dβ = 0.1 ~ 0.4)Additional file 3: Figure S2 shows that participants S2, S3, and S4 have similar distribution of concordant and discordant plots as participant S1.

Fig. 3.

Fig. 3

Comparing methylation values among common CpG sites between MC-seq and EPIC. a Correlation of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S1. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1; b The distribution of median Δβ in common CpG sites between MC-seq and EPIC array. The red dotted line represents Δβ = 0.1 as a cutoff for concordant CpG site between two platforms. c The density plot of methylation values among common CpG sites profiled by MC-seq and EPIC array in participant S1

Table 4.

Discordant CpG sites between MC-seq and EPIC (difference>0.5)

Probe Chr Position Gene MC-seq median EPIC median Median Difference between MC-seq and EPIC Refgene group Relation to CpG island
cg09156519 9 103361572 0.009 0.960 0.95 S_Shore
cg18176117 9 96097296 C9orf129 0.000 0.932 0.93 Body N_Shore
cg14268958 10 133453066 0.000 0.899 0.89 S_Shelf
cg10576280 10 124133822 PLEKHA1 0.072 0.948 0.88 TSS1500 N_Shore
cg01005486 3 13246006 0.047 0.886 0.84 Island
cg23433318 19 667542 0.007 0.866 0.84 Island
cg10766172 7 27498479 0.989 0.147 0.82
cg11812439 4 68928706 LOC550113;SYT14P1;TMPRSS11F 0.973 0.155 0.82 Body; Body; Body
cg23950473 5 154393265 KIF4B; KIF4B 0.992 0.174 0.82 1stExon; 5’UTR
cg00259849 8 4183880 CSMD1 0.000 0.821 0.82 Body
cg23981150 1 161111090 1.000 0.217 0.78 Island
cg09698465 12 133000178 0.906 0.080 0.78 Island
cg20450977 11 10529463 MTRNR2L8; MTRNR2L8 0.964 0.189 0.77 3’UTR; 1stExon
cg01053463 1 26186087 C1orf135 0.021 0.757 0.76 TSS1500 Island
cg12499827 2 202004893 CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR 0.971 0.215 0.76 TSS200; Body; Body; Body; Body; Body; Body; Body; Body
cg03133777 2 170361364 BBS5 1.000 0.244 0.75 3’UTR
cg19040702 17 22023833 0.969 0.230 0.75
cg21675871 11 69813397 0.217 0.960 0.74 Island
cg04240493 3 148414664 AGTR1; AGTR1; AGTR1; AGTR1 0.979 0.258 0.72 TSS1500; TSS1500; TSS1500; TSS1500 N_Shore
cg16889427 10 127584375 FANK1 0.036 0.759 0.71 TSS1500 Island
cg25916505 18 32820654 ZNF397; ZNF397 0.000 0.711 0.71 TSS1500; TSS1500 N_Shore
cg13525026 17 18061071 MYO15A 1.000 0.290 0.71 Body
cg07825433 4 1215099 CTBP1; CTBP1 0.000 0.716 0.71 Body; Body N_Shelf
cg03846641 2 109746751 LOC100287216; SH3RF3 0.239 0.952 0.71 TSS200; Body Island
cg19188207 2 10340837 C2orf48 1.000 0.290 0.71 Body
cg11495544 17 73402155 GRB2; GRB2 0.753 0.049 0.70 TSS1500; TSS1500 S_Shore
cg06931905 8 42036940 PLAT; PLAT 0.896 0.197 0.70 Body; Body
cg03348902 1 569603 0.869 0.168 0.70
cg27120934 6 129480619 LAMA2; LAMA2 0.979 0.297 0.69 Body; Body
cg07576219 1 55012408 ACOT11; ACOT11 0.927 0.250 0.69 TSS1500; TSS1500 S_Shelf
cg08400246 5 156570642 MED7; MED7 0.153 0.870 0.68 TSS1500; TSS1500 S_Shore
cg27626141 8 103876469 AZIN1; AZIN1 0.000 0.682 0.68 TSS200; TSS200 Island
cg26688472 2 203638928 ICA1L 0.984 0.303 0.68 3’UTR Island
cg26101183 10 65930786 0.957 0.279 0.68 Island
cg27090007 13 28519388 ATP5EP2 0.985 0.321 0.67 Body
cg11896012 19 53696753 ZNF665 0.048 0.700 0.67 TSS200 S_Shore
cg02606018 12 10658281 0.979 0.323 0.66
cg00438164 4 100870480 H2AFZ; LOC256880 0.004 0.650 0.65 Body; TSS1500 Island
cg21164300 9 136098495 0.000 0.644 0.64 N_Shelf
cg15891076 10 65930618 0.971 0.328 0.64 Island
cg05948389 5 1641924 0.014 0.660 0.64 N_Shelf
cg10507965 10 102107251 SCD; SCD 0.011 0.642 0.64 5’UTR; 1stExon Island
cg21662326 11 14521493 COPB1; COPB1; COPB1 0.643 0.012 0.63 TSS200; TSS200; TSS200
cg09646578 8 5019363 0.310 0.934 0.63
cg24717964 20 61477008 DPH3B; DPH3B; TCFL5 0.986 0.356 0.63 1stExon; 5’UTR; Body
cg07437919 8 142234483 SLC45A4 0.957 0.313 0.63 Body N_Shore
cg01105403 2 240723304 0.050 0.890 0.63
cg20482143 7 64340804 0.982 0.346 0.63
cg11187452 22 49698612 0.017 0.653 0.63 Island
cg24504954 3 61237217 FHIT; FHIT 0.017 0.649 0.62 TSS200; TSS200 Island
cg27434351 11 14521491 COPB1; COPB1; COPB1 0.639 0.016 0.62 TSS200; TSS200; TSS200
cg15864074 2 120974042 0.976 0.354 0.62
cg00913521 12 89893799 WDR51B 0.977 0.339 0.62 Body
cg27534567 1 568536 0.834 0.262 0.62
cg24515136 17 49024834 0.949 0.328 0.62 S_Shelf
cg01417615 1 52456419 RAB3B 0.629 0.015 0.61 TSS200 Island
cg00236302 12 69004867 RAP1B; RAP1B 0.000 0.612 0.61 5’UTR; 5’UTR Island
cg10747603 22 29197018 XBP1; XBP1 0.022 0.627 0.61 TSS1500; TSS1500 S_Shore
cg03594447 1 20359744 1.000 0.358 0.61
cg23045277 4 190587808 0.299 0.910 0.61
cg02218809 16 29973300 TMEM219; TMEM219 0.020 0.612 0.61 TSS200; TSS200 Island
cg05646491 10 135379754 SYCE1; SYCE1; SYCE1 0.988 0.382 0.60 TSS1500; 5’UTR; TSS1500 Island
cg07596174 20 55926107 RAE1; RAE1 0.014 0.613 0.60 TSS1500; TSS200 N_Shore
cg03543448 16 4384967 GLIS2 0.927 0.315 0.60 Body
cg25793197 5 31923469 PDZD2 0.976 0.379 0.60 Body
cg21392229 2 161223778 RBMS1; RBMS1 1.000 0.384 0.60 Body; Body
cg05607320 12 53342553 KRT18; KRT18 0.064 0.651 0.60 TSS200; TSS1500 N_Shore
cg13896861 9 94878241 SPTLC1; SPTLC1 0.117 0.711 0.60 TSS1500; TSS1500 S_Shore
cg03064900 4 190566141 0.323 0.921 0.60 N_Shore
cg16199859 3 75263685 0.861 0.276 0.60
cg15006843 1 205720633 NUCKS1 0.880 0.260 0.60 TSS1500 S_Shore
cg02498218 4 26361371 RBPJ; RBPJ; RBPJ; RBPJ 0.979 0.388 0.59 Body; Body; 5’UTR; Body Island
cg07116712 15 96887959 0.091 0.681 0.59 Island
cg11643306 20 34204831 SPAG4 0.038 0.630 0.59 Body S_Shore
cg08568561 7 42834498 0.981 0.392 0.59
cg06669598 6 127622363 ECHDC1; ECHDC1; ECHDC1; ECHDC1; ECHDC1 0.984 0.351 0.59 3’UTR; 3’UTR; Body; Body; Body
cg22805431 3 113955600 ZNF80 0.983 0.409 0.59 1stExon
cg24636332 17 4437925 SPNS2 0.301 0.939 0.59 Body N_Shore
cg05924191 15 35279830 ZNF770 0.008 0.605 0.59 5’UTR N_Shore
cg14402194 14 23398944 PRMT5; PRMT5; PRMT5; PRMT5; PRMT5; PRMT5; LOC101926933 0.028 0.592 0.58 TSS200; TSS200; TSS200; TSS200; TSS200; TSS200; Body S_Shore
cg01737532 4 190862170 FRG1 0.000 0.584 0.58 1stExon Island
cg25744017 15 52819324 MYO5A; MYO5A 0.957 0.379 0.58 Body;Body N_Shore
cg03432151 15 89745000 ABHD2; ABHD2 0.948 0.360 0.58 3’UTR; 3’UTR
cg27196695 10 134571377 INPP5A 1.000 0.420 0.58 Body
cg27571351 10 17619364 0.986 0.407 0.58
cg02775804 2 120974080 0.977 0.401 0.58
cg16461530 10 134798264 0.664 0.106 0.58
cg12654770 10 52487693 0.962 0.385 0.58
cg16112880 1 201123745 TMEM9 0.003 0.579 0.58 TSS200 Island
cg20641423 8 125315065 0.911 0.338 0.57 S_Shore
cg23248615 10 2005709 0.905 0.313 0.57
cg25550279 7 53254983 0.965 0.381 0.57 Island
cg01070250 1 569687 0.843 0.271 0.57
cg06977575 4 139481990 0.953 0.376 0.57 Island
cg14511644 9 15055021 0.977 0.399 0.57
cg08947542 8 35383200 UNC5D 0.879 0.309 0.57 Body
cg10258063 2 217363243 RPL37A 0.043 0.613 0.57 TSS1500 N_Shore
cg24209723 18 12913133 0.973 0.399 0.57 S_Shore
cg02265379 5 87898506 LOC645323 0.971 0.384 0.57 Body Island
cg18925601 7 158752715 0.006 0.574 0.57 Island
cg01406075 11 58731104 0.885 0.309 0.57 N_Shore
cg13545297 12 54404315 HOXC8 0.229 0.791 0.57 Body S_Shore
cg09036531 10 96991505 0.968 0.402 0.57
cg25649283 9 140714075 EHMT1 0.382 0.950 0.57 Body Island
cg06204030 17 7792051 CHD3; CHD3; CHD3 0.761 0.141 0.57 TSS200; TSS200; Body S_Shelf
cg18627328 19 621561 POLRMT 0.980 0.411 0.56 Body Island
cg13085681 8 48920761 UBE2V2 0.009 0.576 0.56 TSS1500 N_Shore
cg00999469 6 25107287 CMAHP 0.043 0.931 0.56 Body
cg20960039 9 130213605 LRSAM1; RPL12; LRSAM1; LRSAM1; LRSAM1; RPL12 0.020 0.582 0.56 TSS1500; 1stExon; TSS200; TSS200; TSS200; 5’UTR Island
cg04400841 2 208988863 CRYGD 0.215 0.764 0.56 Body Island
cg12476298 19 58426697 ZNF417 0.977 0.407 0.56 Body N_Shore
cg23997402 19 14275669 LPHN1; LPHN1 0.972 0.442 0.56 Body; Body S_Shore
cg16935370 5 154393281 KIF4B; KIF4B 0.981 0.414 0.56 1stExon; 5′UTR
cg04222159 1 204981786 NFASC; NFASC; NFASC; NFASC 0.630 0.073 0.56 Body; Body; Body; Body
cg06396237 8 120779442 TAF2 0.985 0.430 0.56 Body
cg06599543 6 165749446 PDE10A;PDE10A 0.857 0.332 0.56 Body;Body S_Shore
cg11566832 10 88659593 BMPR1A 0.145 0.693 0.55 Body
cg20334010 15 41047916 RMDN3; RMDN3 0.020 0.570 0.55 TSS1500; TSS1500 S_Shore
cg18245781 5 3659697 0.283 0.852 0.55
cg03761810 2 10264850 RRM2; RRM2 0.018 0.567 0.55 Body; Body S_Shore
cg02122372 3 149657597 RNF13; RNF13 1.000 0.439 0.55 Body; Body
cg06753227 18 9475508 RALBP1 0.000 0.553 0.55 TSS200 Island
cg14131834 13 45914250 LOC100190939; TPT1 0.040 0.594 0.55 TSS1500; Body N_Shore
cg25583180 5 177614382 GMCL1L 1.000 0.451 0.55 Body Island
cg09112623 6 33756905 LEMD2; LEMD2 0.568 0.019 0.55 5’UTR; 1stExon Island
cg11759477 4 190861959 FRG1 0.000 0.548 0.55 TSS200 Island
cg12796755 14 51132292 SAV1 0.932 0.383 0.55 Body N_Shelf
cg19693446 14 102144192 0.958 0.407 0.55
cg25187648 3 49395165 GPX1; GPX1; GPX1 0.018 0.568 0.55 Body; 3’UTR; 1stExon Island
cg20391833 6 167116208 RPS6KA2 0.964 0.431 0.55 Body
cg09705232 6 97611802 MIR548H3; C6orf167 0.974 0.428 0.55 Body; Body
cg04643437 12 14518655 ATF7IP; ATF7IP 0.000 0.561 0.55 1stExon; 5’UTR Island
cg17558062 13 45965415 LOC100190939 1.000 0.456 0.54 Body Island
cg26825848 4 190566175 0.350 0.899 0.54 N_Shore
cg13943141 9 93205862 0.846 0.296 0.54
cg26951705 19 56612697 ZNF787 0.000 0.542 0.54 Body Island
cg24654094 1 160340832 NHLH1 0.964 0.433 0.54 Body Island
cg02996355 14 81879375 0.909 0.364 0.54
cg11914812 12 56904792 1.000 0.459 0.54
cg24895977 19 35861796 0.990 0.450 0.54
cg11637682 6 147124984 LOC729176; C6orf103 0.867 0.300 0.54 TSS200; Body
cg07089633 14 73396378 DCAF4; DCAF4; DCAF4; DCAF4; DCAF4 1.000 0.450 0.54 5’UTR; 5’UTR; 5’UTR; 5’UTR; 5’UTR S_Shelf
cg20360416 4 7246127 SORCS2 0.018 0.659 0.54 Body
cg25627920 17 39992620 NT5C3B; NT5C3B; NT5C3B; KLHL10 0.016 0.552 0.54 TSS200; TSS200; TSS200; TSS1500 Island
cg24000259 5 55488291 ANKRD55 0.961 0.411 0.54 Body
cg09138437 11 64527189 PYGM; PYGM 0.993 0.445 0.54 1stExon; 1stExon
cg02673636 1 109647056 0.976 0.437 0.54 S_Shelf
cg18740872 5 39220260 FYB; FYB 1.000 0.466 0.53 TSS1500; TSS1500
cg14354292 7 63353606 0.960 0.426 0.53
cg17704839 19 9939038 UBL5; UBL5 0.014 0.542 0.53 Body; Body S_Shore
cg05971373 7 157498604 PTPRN2; PTPRN2; PTPRN2 1.000 0.467 0.53 Body; Body; Body S_Shelf
cg05291429 17 1494566 SLC43A2 0.402 0.969 0.53 Body S_Shelf
cg08841342 3 156528470 PA2G4P4 0.976 0.444 0.53 Body
cg04096697 6 37012867 0.983 0.451 0.53 Island
cg26878995 1 168106731 GPR161 0.052 0.570 0.53 TSS1500 S_Shore
cg24031524 20 19804606 0.990 0.468 0.53
cg19311470 4 39460490 RPL9; RPL9; LIAS; LIAS 0.004 0.529 0.53 TSS1500; 5’UTR; TSS200; TSS200 Island
cg02181482 5 178942685 0.956 0.449 0.53
cg05346902 19 47910374 MEIS3; MEIS3 0.068 0.593 0.53 Body; Body Island
cg16470772 10 8203304 0.971 0.445 0.53
cg10115022 1 27527942 0.974 0.464 0.53 Island
cg27231717 6 26319377 0.905 0.386 0.53
cg09451549 19 8386408 RPS28; NDUFA7; RPS28 0.000 0.527 0.53 5’UTR; TSS200; 1stExon Island
cg07628841 2 27851430 GPN1; CCDC121; GPN1; GPN1; CCDC121; CCDC121; GPN1; GPN1 0.010 0.536 0.53 TSS200; 1stExon; TSS200; TSS1500; 5’UTR; 1stExon; TSS200; TSS1500
cg03816081 10 29577743 LYZL1 0.863 0.301 0.52 TSS1500
cg00762003 21 45393541 AGPAT3; AGPAT3 0.383 0.892 0.52 Body; Body Island
cg19466922 7 130138026 MEST; MEST; MEST; MEST; MEST; MEST 1.000 0.476 0.52 Body; Body; Body; Body; Body; Body
cg07712165 17 80899280 TBCD 0.440 0.959 0.52 Body Island
cg01199952 13 25591486 0.984 0.456 0.52 N_Shore
cg11374834 3 75263691 0.950 0.428 0.52
cg02974491 1 1162280 SDF4; SDF4 0.403 0.964 0.52 Body; Body Island
cg10555853 1 33516627 0.929 0.407 0.52 Island
cg21216606 2 207275704 0.985 0.464 0.52
cg17711541 6 26124704 HIST1H2AC; HIST1H2BC 0.007 0.529 0.52 1stExon; TSS1500 Island
cg06412823 7 22541074 STEAP1B; STEAP1B 0.196 0.739 0.52 TSS1500; TSS1500 S_Shore
cg03054343 11 50238214 1.000 0.463 0.52 Island
cg05766605 1 19384827 0.423 0.938 0.52
cg07684215 10 132976057 TCERG1L 0.181 0.923 0.52 Body
cg27193858 6 41169120 TREML2 0.181 0.691 0.52 TSS200
cg00964321 16 15083956 PDXDC1 0.906 0.386 0.52 Body Island
cg25394572 11 56457777 OR8U8 0.949 0.429 0.52 Body
cg10667969 3 149181941 0.967 0.458 0.52
cg18394854 5 8457818 0.212 0.732 0.52 Island
cg05741225 10 133917303 JAKMIP3 0.906 0.370 0.52 TSS1500
cg06026769 12 20704492 PDE3A 0.993 0.473 0.52 Body N_Shore
cg09032630 6 27831956 HIST1H2AL 0.802 0.311 0.52 TSS1500 N_Shore
cg16626480 22 25575426 KIAA1671 0.950 0.422 0.52 Body Island
cg24534731 17 36888147 CISD3 0.969 0.457 0.52 Body S_Shore
cg16202259 14 104625420 KIF26A 0.058 0.962 0.52 Body Island
cg25325592 8 1439535 0.408 0.923 0.52 N_Shore
cg00391025 3 100427239 TFG; TFG 1.000 0.477 0.52 TSS1500; TSS1500 N_Shore
cg25149037 17 39736213 0.820 0.454 0.52
cg19120749 11 1431650 BRSK2; BRSK2; BRSK2; BRSK2; BRSK2; BRSK2 0.468 0.983 0.52 TSS1500; TSS200; Body; Body; Body; Body Island
cg24270624 10 95721318 PIPSL 0.947 0.421 0.52 Body
cg16346588 10 242978 ZMYND11; ZMYND11; ZMYND11 0.970 0.459 0.51 Body; Body; Body
cg02750322 15 83673816 C15orf40; C15orf40; C15orf40; C15orf40; C15orf40 0.966 0.451 0.51 Body; 3’UTR; Body; Body; Body
cg04363536 3 49466872 NICN1 0.000 0.515 0.51 TSS200 S_Shore
cg17883371 1 91359225 1.000 0.480 0.51 Island
cg25018832 1 564471 LOC101928626 0.602 0.088 0.51 TSS200
cg16838729 4 43901032 0.903 0.394 0.51
cg23222247 17 47302219 PHOSPHO1; PHOSPHO1 0.009 0.531 0.51 Body;Body Island
cg19496566 19 48249018 GLTSCR2 0.009 0.535 0.51 1stExon Island
cg03165426 7 30726958 CRHR2; CRHR2 0.429 0.942 0.51 Body; 5’UTR
cg19600494 2 106959525 0.968 0.455 0.51 Island
cg10854807 17 79479308 ACTG1 0.004 0.522 0.51 Body Island
cg20699097 11 111957680 TIMM8B; TIMM8B; SDHD 0.009 0.524 0.51 TSS200; TSS200; 1stExon Island
cg22819767 10 11866910 C10orf47 0.958 0.440 0.51 5’UTR S_Shore
cg20254251 8 144557206 ZC3H3 0.993 0.450 0.51 Body
cg00590830 1 32385224 PTP4A2; PTP4A2; PTP4A2; PTP4A2; PTP4A2 0.971 0.437 0.51 1stExon; 1stExon; 5’UTR; 5’UTR; 5’UTR
cg03877767 2 11680057 GREB1; GREB1 0.172 0.683 0.51 5’UTR; TSS200
cg00487526 15 90818384 0.956 0.444 0.51 Island
cg17501384 2 217364031 RPL37A 0.017 0.521 0.51 Body S_Shore
cg17646418 6 166911767 RPS6KA2; RPS6KA2 0.987 0.468 0.51 Body; Body
cg06757405 5 140789450 PCDHGA4; PCDHGA9; PCDHGA1; PCDHGB1; PCDHGB6; PCDHGB6; PCDHGB3; PCDHGA6; PCDHGA8; PCDHGA5; PCDHGB4; PCDHGA3; PCDHGA2; PCDHGB2; PCDHGA7; PCDHGB5 0.108 0.607 0.51 Body; Body; Body; Body; 1stExon; 1stExon; Body; Body; Body; Body; Body; Body; Body; Body; Body; Body Island
cg13448596 8 2031599 MYOM2 0.381 0.887 0.51 Body
cg16711165 11 111957658 TIMM8B; TIMM8B; SDHD 0.017 0.522 0.51 TSS200; TSS200; 1stExon Island
cg16786640 4 3485263 DOK7; DOK7 0.447 0.954 0.51 Body; Body N_Shore
cg07638938 10 131348599 MGMT 0.986 0.492 0.51 Body
cg05407710 8 143329409 TSNARE1 0.960 0.451 0.51 Body N_Shelf
cg07869994 3 174095190 0.988 0.482 0.51 Island
cg07455406 14 21077527 0.017 0.523 0.51 N_Shore
cg04576847 17 12623611 MYOCD; MYOCD; MYOCD; MYOCD 0.958 0.447 0.51 Body; 5’UTR; Body; 1stExon
cg15699853 18 57684747 0.976 0.467 0.51
cg11231240 8 82434638 1.000 0.482 0.51 Island
cg06157924 4 942005 TMEM175 0.451 0.957 0.51 Body S_Shore
cg23679141 4 165118930 MARCH1; ANP32C 0.946 0.445 0.51 5’UTR; TSS200
cg03053358 17 1029917 ABR; ABR 0.446 0.964 0.51 Body; 5’UTR S_Shore
cg13705894 9 138305338 0.978 0.495 0.51 S_Shore
cg18512780 17 76117734 TMC6; TMC6 0.033 0.529 0.50 Body; Body
cg06307940 16 46660818 0.986 0.487 0.50
cg15541008 5 95297508 ELL2; ELL2 0.000 0.516 0.50 1stExon; 5’UTR S_Shore
cg19969624 13 95954210 ABCC4; ABCC4; ABCC4; ABCC4 0.011 0.507 0.50 TSS1500; TSS1500; TSS1500; TSS1500 Island
cg01758870 7 23719630 C7orf46; C7orf46; C7orf46 0.028 0.545 0.50 TSS200;TSS200;TSS200 Island
cg08323201 15 101835348 SNRPA1 0.000 0.503 0.50 1stExon Island
cg21863998 11 19770288 NAV2; NAV2; NAV2 0.439 0.905 0.50 Body; Body; Body
cg11471802 8 47529015 0.348 0.882 0.50 Island
cg22281935 2 162934111 0.982 0.481 0.50 S_Shelf
cg06032540 15 43941563 CATSPER2; CATSPER2; CATSPER2 1.000 0.500 0.50 TSS1500; TSS1500; TSS1500 Island
cg18761878 1 568475 0.893 0.401 0.50

Density plots of methylation β showed bimodal distribution using both the MC-seq and the EPIC array platforms (Fig. 3c). Density of methylated CpG sites was slightly higher than the density of unmethylated CpG sites on both platforms. However, the two peaks in the EPIC array density plot were closer than the two peaks in the MC-seq density plot (Fig. 3c), indicating that MC-seq captures a higher dynamic range (i.e., more methylated and unmethylated) of CpG sites than the EPIC array. Additional file 4: Figure S3 shows that participants S2, S3, and S4 have similar density plots.

Discussion

We profiled the same PBMC samples using the MC-seq and EPIC array platforms and compared their performance. Our results show that the Agilent SureSelect Methyl-Seq targeted enrichment platform produced high-quality DNA methylation sequencing data at single base-pair resolution. MC-seq can reliably detect CpG sites with DNA input quantities as low as 300 ng. Overall, MC-seq detected 3–4 times more CpG sites than the EPIC array; however, the proportion of CpG sites mapped on functional genomic regions was similar between the two platforms. Methylation at a majority of CpG sites between the two platforms was highly correlated, while methylation at a low percentage of CpG sites differed significantly between the two platforms. Specifically, we found that methylation at 239 CpG sites differed significantly between the two platforms with absolute Δβ values greater than 0.5, which suggests that these CpG sites should be interpreted with caution in EWAS studies.

Our results show that MC-seq produces highly reliable CpG site methylation estimates across the genome. The observed CpG-based reproducibility is high, suggesting that technical variation on CpG calls is low. Inter-personal methylation variation is important for EWAS analysis. We found that our participant-based methylation on common CpG sites across four participants is also highly correlated, which further demonstrates the high reproducibility of this platform.

One disadvantage of sequencing-based approaches is the requirement for a larger quantity of input DNA than array-based approaches for methylation profiling. The recommended input DNA for Agilent SureSelect platform is 1ug, while input DNA quantity for EPIC array can be as low as 250 ng. Input DNA quantity is one important consideration influencing study design and methylation assay platform selection for population-based EWAS. Agilent has reported that DNA quantity can be as low as 250 ng for SureSelect sequencing [14]. To examine whether DNA quantity impacts the performance of MC-seq and to test whether low input DNA quantity also produces reliable CpG detection, we compared the capacity of CpG site detection across three different DNA input quantities. We found that medium DNA input quantity (i.e., 300 ng to 1000 ng) reliably detected CpG sites is comparable to the number of CpG sites captured by high DNA input quantity (i.e., greater than 1000 ng). Low DNA input quantity (i.e., less than 300 ng) detected the lowest number of CpG sites compared with high and medium DNA input quantity. For samples with low DNA input quantity, additional PCR cycles are needed to ensure post-capture library yield that results in extensive duplicate reads. In the four low DNA input samples, the duplicate rate exceeds 80%. Thus, removing duplicate reads is an important step in the QC process for MC-seq. We found that the number of CpG sites in low DNA input samples without duplicated reads still is significantly higher than the number of CpG sites detected by the EPIC array.

Consistent with previous reports, we found that methylation at the majority of CpG sites measured by both approaches (> 98%) is highly consistent between MC-seq and array-based methods. However, we identified 1.4% of CpG sites with discrepancies in CpG methylation that exceeds 10%. More importantly, 239 out of 60,753 discordant CpG sites had methylation differences exceeding 50%. These CpG sites are located on 159 gene regions (Table 4). Some of these genes have been previously reported to be associated with diseases. For example, SLC45A4 was reported to harbor an epigenetic marker for adiposity [21]. The methylation β differs on the CpG site of this gene by as much as 0.63 between the two platforms. We have also identified those CpG sites that showed less but still apparent discrepancy between the two assay platforms (i.e., absolute difference of beta values between 0.1 and 0.5). The top 100 CpG sites discrepant in a range of 0.1–0.4 between two platforms are presented in Table S2 to allow investigators to consider this potential source of bias in EWAS findings. The discrepancy might be due to bias in the performance of the beadchip assay at these positions, sequence context-dependent impacts on the performance of sequencing, batch effects, or a combination of these possibilities. This large discrepancy warrants further investigation and interpretation of findings at these CpG sites must be interpreted with caution.

One of the limitations of this study is the small number of participants used to estimate inter-sample variability. A previous study used a benchmark approach to evaluate performance of different platforms [17] and concluded that the EPIC array performed better than the MC-seq platform. However, the study did not remove duplicate reads as part of their data processing, which may have compromised the QC for MC-seq data processing as discussed above. Future studies, including benchmarking using a larger sample size, could further improve the analysis of platform performance. Of note, MC-seq detected high percentages of CHG and CHH sites across four methylome, which is consistent with previous reports [15]. The significances of those methylation sites warrant further investigation.

New approaches to measurement of DNA methylation continue to emerge that may warrant similar investigation in an ongoing effort to provide users with empiric comparisons to inform decisions about platform selection. One recent approach is enzymatic methyl-sequencing (EM-seq) (e.g., NEBNext EM-seq by New England Biolabs, Ipswich, MA) [22]. The input genomic DNA requirement is low 10–200 ng and EM-seq has comparable performance to WGBS [22], but its performance in relation to array- or capture sequencing-based approaches has not been reported. Should EM-seq gain popularity, it would be important to directly compare the performance of MC-seq and EM-seq to provide empiric evidence to users to inform platform selection.

Nevertheless, we have demonstrated that MC-seq is an efficient, reliable, and affordable platform that allows medium input quantity of DNA input (i.e., > 300 ng), which is equivalent to DNA input required for EPIC array. MC-seq has the advantage of capturing significantly more CpG sites than the EPIC array. Although methylation measurements between the two platforms are highly consistent, we have identified a small number of CpG sites that must be interpreted with caution if they are associated with a trait of interest because they showed significant discrepancies between the two platforms.

Conclusions

Our results show that MC-seq is an efficient and reliable platform for methylome profiling with a broader coverage of the methylome than the array-based platform. Although methylation measurements in majority of CpGs are highly correlated, a number of CpG sites show large discrepancy between the two platforms, which warrants further investigation and needs cautious interpretation.

Supplementary information

13072_2020_372_MOESM1_ESM.pdf (2.6MB, pdf)

Additional file 1: Figure S1. A Manhattan plot showing the distribution of Δβ between MC-seq and EPIC array in PBMC by chromosome positions. Blue line represents Δβ = 0.1 and red line represents Δβ = 0.5.

13072_2020_372_MOESM2_ESM.xlsx (15.3KB, xlsx)

Additional file 2: Table S1. Top 100 discordant CpG sites between MC-seq and EPIC array (Δβ = 0.1 ~ 0.4).

13072_2020_372_MOESM3_ESM.pdf (8.2MB, pdf)

Additional file 3: Figure S2. Comparison of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S2, S3, and S4. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1

13072_2020_372_MOESM4_ESM.pdf (4.3MB, pdf)

Additional file 4: Figure S3. The density plot of methylation values among CpG sites assayed in common by MC-seq and EPIC array in participant S2, S3, and S4

Acknowledgements

The project was supported by the National Institute on Drug Abuse (R03DA039745, R01DA038632, R01DA047063, R01DA047820). The authors appreciate the support of the Yale Center of Genomic Analysis and Women’s Interagency HIV Study.

Abbreviations

EM-seq

Enzymatic methyl-seq

EPIC

Illumina Infinium MethylationEPIC Beadchip

EWAS

Epigenome-wide association study

MC-seq

Methylation capture sequencing

PBMC

Peripheral blood mononuclear cell

PCR

Polymerase chain reaction

QC

Quality control

RTA

Real-time analysis

TTS

Transcription termination site

WGBS

Whole-genome bisulfite sequencing

Authors’ contributions

CS contributed to data analysis and the first draft of manuscript. XZ contributed to data processing, quality control, analysis, and manuscript preparation. BA was involved in manuscript preparation and provided peripheral blood monocyte cells. KX contributed to study design, analytical strategies, and manuscript preparation. All the authors read and approved the final manuscript.

Data availability

All methylation data from MC-seq and EPIC platforms are deposited in GEO (GSE152922).

Ethics approval and consent to participate

The study was approved by the committee of the Human Research Subject Protection at Yale University and the Institutional Research Board Committee of the Connecticut Veteran Healthcare System. De-identifiable samples were from Women’s Interagency HIV Study cohort. All participants provided written consents.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13072-020-00372-6.

References

  • 1.Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: a systematic review on DNA methylation mechanisms. J Psychosom Res. 2017;92:34–44. doi: 10.1016/j.jpsychores.2016.11.005. [DOI] [PubMed] [Google Scholar]
  • 2.Kraiczy J, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. Gut. 2019;68(1):49–61. doi: 10.1136/gutjnl-2017-314817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta Rev Cancer. 2016;1866(1):106–120. doi: 10.1016/j.bbcan.2016.07.001. [DOI] [PubMed] [Google Scholar]
  • 4.Li M, D’Arcy C, Li X, Zhang T, Joober R, Meng X. What do DNA methylation studies tell us about depression? A systematic review. Transl Psychiatry. 2019;9(1):68. doi: 10.1038/s41398-019-0412-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-wide association study identifies methylation sites associated with liver enzymes and hepatic steatosis. Gastroenterology. 2017;153(4):1096–1106. doi: 10.1053/j.gastro.2017.06.003. [DOI] [PubMed] [Google Scholar]
  • 6.Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review. BMC Genet. 2016;17(1):27. doi: 10.1186/s12863-016-0332-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci. 2013;14(7):15029–15058. doi: 10.3390/ijms140715029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13–27. doi: 10.1016/j.ccr.2009.11.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010;12(3):R36. doi: 10.1186/bcr2590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109–127. doi: 10.1038/s41576-018-0074-2. [DOI] [PubMed] [Google Scholar]
  • 11.Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403–418. doi: 10.1038/s41591-019-0376-8. [DOI] [PubMed] [Google Scholar]
  • 12.Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview of Infinium HumanMethylation450 data processing. Brief Bioinform. 2013;15(6):929–941. doi: 10.1093/bib/bbt054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17(1):1–17. doi: 10.1186/s13059-016-1066-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang JZ, Pabon C, Napier M. Agilent SureSelectXT Methyl-Seq applications with low-input DNA and smaller capture libraries. 2017. https://www.agilent.com/cs/library/applications/5991-7838EN.pdf.
  • 15.Teh AL, Pan H, Lin X, Lim YI, Patro CP, Cheong CY, et al. Comparison of methyl-capture sequencing vs. Infinium 450 K methylation array for methylome analysis in clinical samples. Epigenetics. 2016;11(1):36–48. doi: 10.1080/15592294.2015.1132136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sun Z, Cunningham J, Slager S, Kocher JP. Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis. Epigenomics. 2015;7(5):813–828. doi: 10.2217/epi.15.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Heiss JA, Brennan KJ, Baccarelli AA, Tellez-Rojo MM, Estrada-Gutierrez G, Wright RO, et al. Battle of epigenetic proportions: comparing Illumina’s EPIC methylation microarrays and TruSeq targeted bisulfite sequencing. Epigenetics. 2020;15(1–2):174–182. doi: 10.1080/15592294.2019.1656159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wreczycka K, Gosdschan A, Yusuf D, Gruning B, Assenov Y, Akalin A. Strategies for analyzing bisulfite sequencing data. J Biotechnol. 2017;261:105–115. doi: 10.1016/j.jbiotec.2017.08.007. [DOI] [PubMed] [Google Scholar]
  • 19.Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571–1572. doi: 10.1093/bioinformatics/btr167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhang X, Hu Y, Justice AC, Li B, Wang Z, Zhao H, et al. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. Nat Commun. 2017;8(1):2243. doi: 10.1038/s41467-017-02326-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lillycrop KA, Garratt ES, Titcombe P, Melton PE, Murray RJ, Barton SJ, et al. Differential SLC6A4 methylation: a predictive epigenetic marker of adiposity from birth to adulthood. Int J Obes. 2019;43(5):974–988. doi: 10.1038/s41366-018-0254-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Williams L, Bei Y, Church HE, Dai N, Dimalanta ET, Ettwiller LM, et al. Enzymatic Methyl-seq: the next generation of methylome analysis. NEB Expressions. 2019;.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13072_2020_372_MOESM1_ESM.pdf (2.6MB, pdf)

Additional file 1: Figure S1. A Manhattan plot showing the distribution of Δβ between MC-seq and EPIC array in PBMC by chromosome positions. Blue line represents Δβ = 0.1 and red line represents Δβ = 0.5.

13072_2020_372_MOESM2_ESM.xlsx (15.3KB, xlsx)

Additional file 2: Table S1. Top 100 discordant CpG sites between MC-seq and EPIC array (Δβ = 0.1 ~ 0.4).

13072_2020_372_MOESM3_ESM.pdf (8.2MB, pdf)

Additional file 3: Figure S2. Comparison of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S2, S3, and S4. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1

13072_2020_372_MOESM4_ESM.pdf (4.3MB, pdf)

Additional file 4: Figure S3. The density plot of methylation values among CpG sites assayed in common by MC-seq and EPIC array in participant S2, S3, and S4

Data Availability Statement

All methylation data from MC-seq and EPIC platforms are deposited in GEO (GSE152922).


Articles from Epigenetics & Chromatin are provided here courtesy of BMC

RESOURCES